menu
    • menu
    [{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Not Applicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Not Applicable"},{"orgOrder":0,"company":"Kiq","sponsor":"Unum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"PLX9486","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kiq","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Kiq \/ Unum Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Kiq \/ Unum Therapeutics"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Not Applicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Oncology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"Cytotoxic CD8 T Cell","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Not Applicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Oncology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Cogent Biosciences \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Oncology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Cogent Biosciences \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Bezuclastinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Bezuclastinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGFRA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGFRA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGFRA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGFRA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGFRA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGFRA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Sunitinib

    Menu

    Sunitinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cogent Biosciences

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Cogent Biosciences

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bezuclastinib,Sunitinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cogent Completes Enrollment in Phase 3 PEAK Trial for Gastrointestinal Stromal Tumors

                            Details : CGT9486 (bezuclastinib), is a KIT mutant inhibitor, being investigated in combination with sunitinib for patients living with gastrointestinal stromal tumors.

                            Product Name : CGT9486

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 03, 2024

                            Lead Product(s) : Bezuclastinib,Sunitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cogent Biosciences

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Cogent Biosciences

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bezuclastinib,Sunitinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $225.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

                            Details : The net proceeds will be used for the clinical development of CGT9486 (bezuclastinib), which is a KIT mutant inhibitor for systemic mastocytosis and gastrointestinal stromal tumors.

                            Product Name : CGT9486

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 14, 2024

                            Lead Product(s) : Bezuclastinib,Sunitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $225.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cogent Biosciences

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Cogent Biosciences

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bezuclastinib,Sunitinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

                            Details : Cogent intends to fund the development, regulatory and commercial preparation activities relating to CGT9486 (bezuclastinib), a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in ...

                            Product Name : CGT9486

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 06, 2023

                            Lead Product(s) : Bezuclastinib,Sunitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ipsen

                            France arrow
                            PharmScience R&D
                            Not Confirmed

                            Ipsen

                            France arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cabozantinib,Nivolumab,Sunitinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cabometyx® In Combination with Nivolumab Shows Durable Survival Benefits at Over Three-Years’ Follow-Up in ...

                            Details : Cabometyx (cabozantinib) is a multiple receptor tyrosine kinases inhibitor. These receptors are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, maintenance of the tumor microenvironm...

                            Product Name : Cabometyx

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            February 13, 2023

                            Lead Product(s) : Cabozantinib,Nivolumab,Sunitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cogent Biosciences

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Cogent Biosciences

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bezuclastinib,Sunitinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Jefferies

                            Deal Size : $172.6 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Fu...

                            Details : The net proceeds from the offering will be used for development, regulatory and commercial preparation activities relating to CGT9486 (bezuclastinib) and other product candidates, as well as for working capital and general corporate purposes.

                            Product Name : CGT9486

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 16, 2022

                            Lead Product(s) : Bezuclastinib,Sunitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Jefferies

                            Deal Size : $172.6 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cogent Biosciences

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Cogent Biosciences

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bezuclastinib,Sunitinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Jefferies

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warra...

                            Details : Cogent intends to use the net proceeds from the offering for development, regulatory and commercial preparation activities relating to CGT9486 (bezuclastinib) and other product candidates, as well as for working capital and general corporate purposes.

                            Product Name : CGT9486

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 14, 2022

                            Lead Product(s) : Bezuclastinib,Sunitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Jefferies

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ipsen

                            France arrow
                            PharmScience R&D
                            Not Confirmed

                            Ipsen

                            France arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cabozantinib,Nivolumab,Sunitinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Diffe...

                            Details : Updated outcomes from trial evaluating combination of Cabometyx (Cabozantinib) plus atezolizumab in an expanded patient population in NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune che...

                            Product Name : Cabometyx

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            May 26, 2022

                            Lead Product(s) : Cabozantinib,Nivolumab,Sunitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            CalciMedica

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            CalciMedica

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sunitinib

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit Meeti...

                            Details : GB-102 is a microparticle formulation of a pan-VEGF inhibitor, sunitinib, for the treatment of wet age-related macular degeneration designed for a twice-per-year intravitreal injection. GB-102 has the potential to also benefit patients with diabetic reti...

                            Product Name : GB-102

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            May 19, 2022

                            Lead Product(s) : Sunitinib

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Mendus

                            Sweden arrow
                            PharmScience R&D
                            Not Confirmed

                            Mendus

                            Sweden arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ilixadencel,Sunitinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immunicum AB: Immunicum Publishes Phase II MERECA Trial Results of Ilixadencel in Kidney Cancer in European Ur...

                            Details : The MERECA study showed that the combination of ilixadencel with the tyrosine kinase inhibitor sunitinib was safe and associated with a positive trend for improved tumor response rate and overall survival, compared with sunitinib monotherapy (control gro...

                            Product Name : Intuvax

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 28, 2022

                            Lead Product(s) : Ilixadencel,Sunitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cogent Biosciences

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Cogent Biosciences

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bezuclastinib,Sunitinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022

                            Details : Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).

                            Product Name : CGT9486

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 08, 2022

                            Lead Product(s) : Bezuclastinib,Sunitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth